Richard Gless Selected Research

1- (1- acetyl- piperidine- 4- yl)- 3- adamantan- 1- yl- urea

3/2012	Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.
2/2011	1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard Gless Research Topics

Disease

2	Hypertension (High Blood Pressure) 03/2012 - 02/2011
1	Type 2 Diabetes Mellitus (MODY) 03/2012
1	Insulin Resistance 02/2011
1	Obesity 02/2011
1	Vascular Remodeling 09/2009
1	Abdominal Aortic Aneurysm 09/2009
1	Dyslipidemias (Dyslipidemia) 09/2009
1	Atherosclerosis 09/2009

Drug/Important Bio-Agent (IBA)

3	Epoxide HydrolasesIBA 03/2012 - 09/2009
2	1- (1- acetyl- piperidine- 4- yl)- 3- adamantan- 1- yl- ureaIBA 03/2012 - 02/2011
2	Angiotensin IIIBA 02/2011 - 09/2009
1	Glucose (Dextrose)FDA LinkGeneric 02/2011
1	ApolipoproteinsIBA 09/2009

Therapy/Procedure

1	Ligation 09/2009